[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
Identifieur interne : 000806 ( Main/Merge ); précédent : 000805; suivant : 000807[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
Auteurs : P. Cesaro [France] ; L. Defebvre [France]Source :
- Revue neurologique [ 0035-3787 ] ; 2014.
English descriptors
- KwdEn :
- Aged, Antidepressive Agents (therapeutic use), Antiparkinson Agents (therapeutic use), Female, Humans, Indans (adverse effects), Indans (therapeutic use), Male, Middle Aged, Neuroprotective Agents (adverse effects), Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (psychology).
- MESH :
- chemical , adverse effects : Indans, Neuroprotective Agents.
- chemical , therapeutic use : Antidepressive Agents, Antiparkinson Agents, Indans, Neuroprotective Agents.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Aged, Female, Humans, Male, Middle Aged.
Abstract
In this article, we discuss the management of motor symptoms during the early phases of Parkinson's disease, excluding that of any other clinical manifestation. We relied primarily upon recently published data and do not describe older publications relating to anticholinergic drugs or amantadine. The initial pharmacological treatment of idiopathic Parkinson's disease (IPD) is symptomatic and remains based upon dopaminergic drugs. However, the development of new drugs has broadened the range of strategic options and improved overall patient management. Announcing the diagnosis is a critical moment, as pointed out by patients' associations. Patients should be advised to maintain personal, professional, social and physical activities as long as possible. The potential benefit of early pharmacological treatment should be explained, focusing on the possible disease-modifying effect of drugs such as rasagiline. According to current guidelines, L-Dopa is preferred in patients above 65years of age, while those below 65 should be treated with dopamine agonists. Like monoamine oxidase inhibitors B (MAOI-B), synthetic dopamine agonists exhibit several advantages: easy-to-use treatment with a once-daily administration, delayed L-Dopa initiation, significant efficacy on motor symptoms (although lower than that of L-Dopa). MOAI can be prescribed in association with L-Dopa or dopamine agonists. Rasagiline also delays L-Dopa initiation, and consequently motor complications.
DOI: 10.1016/j.neurol.2013.10.015
PubMed: 24673985
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000589
- to stream PubMed, to step Curation: 000569
- to stream PubMed, to step Checkpoint: 000569
- to stream Ncbi, to step Merge: 001371
- to stream Ncbi, to step Curation: 001371
- to stream Ncbi, to step Checkpoint: 001371
Links to Exploration step
pubmed:24673985Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].</title><author><name sortKey="Cesaro, P" sort="Cesaro, P" uniqKey="Cesaro P" first="P" last="Cesaro">P. Cesaro</name><affiliation wicri:level="3"><nlm:affiliation>Département de neurosciences cliniques, pôle neurolocomoteur, Inserm U955, équipe NPI, hôpital Henri-Mondor, groupe hospitalier Henri-Mondor, université UPEC-Paris XII Créteil, bâtiment R, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de neurosciences cliniques, pôle neurolocomoteur, Inserm U955, équipe NPI, hôpital Henri-Mondor, groupe hospitalier Henri-Mondor, université UPEC-Paris XII Créteil, bâtiment R, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><affiliation wicri:level="3"><nlm:affiliation>Service de neurologie et pathologie du mouvement, pôle de neurosciences et de l'appareil locomoteur, hôpital Salengro, EA 1046, faculté de médecine, université Lille Nord-de-France, avenue du Pr-Émile-Laine, 59037 Lille cedex, France. Electronic address: luc.defebvre@chru-lille.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de neurologie et pathologie du mouvement, pôle de neurosciences et de l'appareil locomoteur, hôpital Salengro, EA 1046, faculté de médecine, université Lille Nord-de-France, avenue du Pr-Émile-Laine, 59037 Lille cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24673985</idno><idno type="pmid">24673985</idno><idno type="doi">10.1016/j.neurol.2013.10.015</idno><idno type="wicri:Area/PubMed/Corpus">000589</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000589</idno><idno type="wicri:Area/PubMed/Curation">000569</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000569</idno><idno type="wicri:Area/PubMed/Checkpoint">000569</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000569</idno><idno type="wicri:Area/Ncbi/Merge">001371</idno><idno type="wicri:Area/Ncbi/Curation">001371</idno><idno type="wicri:Area/Ncbi/Checkpoint">001371</idno><idno type="wicri:doubleKey">0035-3787:2014:Cesaro P:drug:treatment:of</idno><idno type="wicri:Area/Main/Merge">000806</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].</title><author><name sortKey="Cesaro, P" sort="Cesaro, P" uniqKey="Cesaro P" first="P" last="Cesaro">P. Cesaro</name><affiliation wicri:level="3"><nlm:affiliation>Département de neurosciences cliniques, pôle neurolocomoteur, Inserm U955, équipe NPI, hôpital Henri-Mondor, groupe hospitalier Henri-Mondor, université UPEC-Paris XII Créteil, bâtiment R, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Département de neurosciences cliniques, pôle neurolocomoteur, Inserm U955, équipe NPI, hôpital Henri-Mondor, groupe hospitalier Henri-Mondor, université UPEC-Paris XII Créteil, bâtiment R, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex</wicri:regionArea><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Créteil</settlement></placeName></affiliation></author><author><name sortKey="Defebvre, L" sort="Defebvre, L" uniqKey="Defebvre L" first="L" last="Defebvre">L. Defebvre</name><affiliation wicri:level="3"><nlm:affiliation>Service de neurologie et pathologie du mouvement, pôle de neurosciences et de l'appareil locomoteur, hôpital Salengro, EA 1046, faculté de médecine, université Lille Nord-de-France, avenue du Pr-Émile-Laine, 59037 Lille cedex, France. Electronic address: luc.defebvre@chru-lille.fr.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de neurologie et pathologie du mouvement, pôle de neurosciences et de l'appareil locomoteur, hôpital Salengro, EA 1046, faculté de médecine, université Lille Nord-de-France, avenue du Pr-Émile-Laine, 59037 Lille cedex</wicri:regionArea><placeName><region type="region" nuts="2">Hauts-de-France</region><region type="old region" nuts="2">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author></analytic><series><title level="j">Revue neurologique</title><idno type="ISSN">0035-3787</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antidepressive Agents (therapeutic use)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Indans (adverse effects)</term><term>Indans (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (adverse effects)</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Indans</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antidepressive Agents</term><term>Antiparkinson Agents</term><term>Indans</term><term>Neuroprotective Agents</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In this article, we discuss the management of motor symptoms during the early phases of Parkinson's disease, excluding that of any other clinical manifestation. We relied primarily upon recently published data and do not describe older publications relating to anticholinergic drugs or amantadine. The initial pharmacological treatment of idiopathic Parkinson's disease (IPD) is symptomatic and remains based upon dopaminergic drugs. However, the development of new drugs has broadened the range of strategic options and improved overall patient management. Announcing the diagnosis is a critical moment, as pointed out by patients' associations. Patients should be advised to maintain personal, professional, social and physical activities as long as possible. The potential benefit of early pharmacological treatment should be explained, focusing on the possible disease-modifying effect of drugs such as rasagiline. According to current guidelines, L-Dopa is preferred in patients above 65years of age, while those below 65 should be treated with dopamine agonists. Like monoamine oxidase inhibitors B (MAOI-B), synthetic dopamine agonists exhibit several advantages: easy-to-use treatment with a once-daily administration, delayed L-Dopa initiation, significant efficacy on motor symptoms (although lower than that of L-Dopa). MOAI can be prescribed in association with L-Dopa or dopamine agonists. Rasagiline also delays L-Dopa initiation, and consequently motor complications.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000806 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 000806 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Merge
|type= RBID
|clé= pubmed:24673985
|texte= [Drug treatment of early-stage (de novo and "honeymoon") Parkinson disease].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Merge/RBID.i -Sk "pubmed:24673985" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |